Fluorescent Phospholipase Assay for PLA2 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inhibiting phospholipase A2 activity in the context of inflammatory diseases, such as cystic fibrosis, are ineffective due to side effects and the complexity of PLA2 isoforms, leading to uncontrolled production of lipid mediators and tissue damage.
Innovation Solution
A fluorescently labeled liposome-based method for measuring phospholipase activity, specifically detecting PLA2 stimulators and inhibitors, including the use of α1-antitrypsin and mercaptalbumin, to modulate PLA2 activity and diagnose lung inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to inhibit phospholipase A2 activity, then some inhibition effect is achieved, but side effects occur and the complexity of PLA2 isoforms makes the approach ineffective
Solution Approach 1:
The patent uses fluorescently labeled liposomes as intermediary substrates to detect PLA2 activity indirectly. Instead of directly inhibiting PLA2 with potentially harmful compounds, the invention employs fluorescent probes that bind to PLA2 and emit detectable signals, allowing for safe measurement and monitoring of enzyme activity without the side effects associated with direct inhibition methods
Solution Approach 2:
The patent changes the detection parameter from direct measurement of PLA2 inhibition to fluorescent signal detection. By using fluorescently labeled substrates that change emission properties upon enzymatic cleavage, the method transforms an complex biochemical inhibition problem into a simple optical detection problem, enabling reliable measurement without side effects
2Measurement precision
If conventional assays are used to measure phospholipase activity, then basic activity detection is possible, but measurement precision is insufficient for diagnosing inflammatory diseases
Solution Approach 1:
The patent employs fluorescent color changes as the basis for precise measurement. The fluorescently labeled liposomes emit specific wavelengths of light that change intensity or pattern upon enzymatic cleavage by PLA2, providing highly sensitive and precise quantitative measurement of enzyme activity that far exceeds conventional colorimetric or radiometric assays
Solution Approach 2:
The patent replaces complex mechanical or biochemical measurement systems with optical detection. Instead of using elaborate separation, filtration, or radioactivity measurement apparatus, the invention uses simple fluorescence detection to achieve high-precision measurement of PLA2 activity, dramatically simplifying the device while improving measurement capability
3Object-generated harmful factors
If PLA2 inhibitors are administered to reduce lipid mediator production, then inflammatory responses may be reduced, but uncontrolled production of lipid mediators continues due to ineffective inhibition
Solution Approach 1:
The patent implements a feedback mechanism for controlling PLA2 activity. By using the fluorescent assay to continuously monitor enzyme activity levels, clinicians can adjust inhibitor dosages to maintain PLA2 activity within therapeutic ranges, preventing both uncontrolled lipid mediator production and excessive inhibition that could cause side effects
Solution Approach 2:
The patent enables preliminary assessment of individual patient PLA2 activity levels before initiating inhibitor therapy. The fluorescent assay provides baseline measurements that allow for personalized treatment planning, ensuring that inhibitors are administered at appropriate doses from the start to effectively control lipid mediator production while minimizing side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise measurement and modulation of PLA2 activity, potentially reducing inflammatory responses and tissue damage in conditions like cystic fibrosis, offering a diagnostic and therapeutic tool for managing PLA2-related disorders.
Implementation Method 1
a fluorescently labeled molecule selected from a fluorescently labeled PC or a fluorescently labeled, negatively charged phospholipid wherein hydrolizaton of the phospholipid components of the liposome by the phospholipase causes a fluorescence intensity change
Data Source
AI summary
A fluorescent phospholipase assay is disclosed. Further disclosed are the identification of alpha-1-antitrypsin as a phospholipase A2 stimulator and phospholipase C inhibitor and the identification of mercaptalbumin as a phospholipase A2 inhibitor. Various applications involving the use of the phospholipase assay, alpha-1-antitrypsin and mercaptalbumin are also disclosed.